

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**VOLUNTARY ANNOUNCEMENT  
INITIATION OF PHASE I/II CLINICAL TRIAL AND  
COMPLETION OF FIRST PATIENT ENROLLMENT  
IN PHASE I CLINICAL TRIAL FOR  
RECOMBINANT POLIOMYELITIS VACCINE IN INDONESIA**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that the Phase I/II clinical trial for the Recombinant Poliomyelitis Vaccine (“**CS-2036**”) developed by the Company was officially initiated in Indonesia recently and the first trial patient case of the Phase I clinical trial has been formally enrolled.

Based on the protein structure design and virus-like particle (“**VLP**”) assembly technology of the Company, CS-2036 candidate is a non-infectious polio VLP vaccine with good safety and immunogenicity profiles that does not rely on live virus in the manufacturing process. Non-infectious polio VLP-based vaccines are recommended by the World Health Organization as one of the preferred vaccines for polio in the future, expected to be an ideal post-eradication polio vaccine.

The Phase I/II clinical trials will further evaluate the safety and immunogenicity of CS-2036 in infants and toddlers in certain ages.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, December 20, 2024

*As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.*